Quality of Life Assessments Utilized in Vitiligo Clinical Trials
Table 2
Breakdown of included vitiligo clinical trials assessing QoL measures.
Parameter of interest
Outcome in QoL studies
Outcome in non-QoL studies
value using Fischer’s exact test
Number of clinical trials
24 total studies
36 total studies
= 0.002
Phase 2: n (%)
17 (47.22%)
19 (55.88%)
Phase 3: n (%)
7 (58.33%)
5 (13.89%)
Unspecified:n (%)
0 (0.00%)
12 (33.33%)
Specific indication
= 0.288
Vitiligo, n (%)
18 (75.00%)
31 (86.11%)
Nonsegmental vitiligo, n (%)
6 (25.00%)
4 (11.11%)
Unspecified/other, n (%)
0 (0.00%)
1 (2.78%)
Gender
= 0.400
All
23 (95.83%)
36 (100.00%)
Male only
1 (4.17%)
0 (0.00%)
Female only
0 (0.00%)
0 (0.00%)
Enrollment, n
= 0.063
0–20
7 (29.17%)
8 (22.22%)
20–50
8 (33.33%)
16 (44.44%)
50–100
1 (4.17%)
8 (22.22%)
100+
8 (33.33%)
4 (11.11%)
Date of clinical trial
p = 0.199
2000–2005
1 (4.17%)
0 (0.00%)
2006–2010
0 (0.00%)
7 (19.44%)
2011–2015
6 (25.00%)
11 (30.56%)
2016–2020
8 (33.33%)
7 (19.44%)
2021–present
9 (37.50%)
11 (30.56%)
Type of intervention
p = 0.022
Medication (pharmaceutical)
18 (75.00%)
19 (52.78%)
Laser/photo/other (nonpharmaceutical)
1 (4.17%)
12 (33.33%)
Medication + laser/photo/other (both)
5 (20.83%)
5 (13.89%)
Location
p = 0.029
Within US
16 (66.67%)
13 (36.11%)
Outside US
7 (29.17%)
22 (61.11%)
Unknown
1 (4.17%)
1 (2.78%)
QoL as outcome measure
N/A
N/A
Primary measure, n (%)
1 (4.17%)
Secondary measure, n (%)
22 (91.67%)
Other, n (%)
1 (4.17%)
Number of QoL measures assessed
N/A
N/A
One
19 (79.17%)
Two
5 (20.83%)
QOL measurement used
29 total
N/A
N/A
DLQI, n (%)
16 (55.17%)
CDLQI, n (%)
4 (13.79%)
VitiQoL, n (%)
4 (13.79%)
VIS, n (%)
1 (3.45%)
Patient satisfaction, n (%)
2 (6.90%)
Patient global assessment, n (%)
1 (3.45%)
Unspecified, n (%)
1 (3.45%)
Includes trials listed as phase 1 and 2 and phase 2 and 3. QoL = quality of life; DLQI = Dermatology Life Quality Index; CDLQI = Child Dermatology Life Quality Index; VitiQoL = Vitiligo Quality of Life Index; VIS = vitiligo impact scale.
